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ABSTRACT We have validated a method for extracting
and measuring the tissue content of somatomedin C (Sm-
C)/insulin-like growth factor I (IGF-I), a growth-hormone-de-
pendent, growth-promoting peptide. The Sm-C content of tis-
sue extracts was strongly growth-hormone dependent because
most of the tissues studied from hypophysectomized rats con-
tained significantly less Sm-C than normal tissues. The intra-
peritoneal administration of ovine growth hormone (oGH) to
hypophysectomized rats caused tissue extractable Sm-C to in-
crease in kidney, liver, lung, heart, and testes. Tissue Sm-C
responses to oGH were maximal after 12 hr, 6 hr before the
maximal increment in serum. In liver and lung, the tissue Sm-
C response to various doses of oGH fit linear regression mod-
els, and the doses of oGH needed to increase the Sm-C are in
the range of those required to increase protein synthesis. Al-
though these results do not exclude the possibility that the so-
matomedins act by hormone-like endocrine mechanisms, they
add support to the concept that these peptides act through au-
tocrine or paracrine mechanisms, being produced at multiple
sites and acting at or near their sites of production.
There is now evidence that somatomedins, traditionally con-
sidered to originate in the liver, are synthesized at multiple
sites (1, 2). Using explant cultures, we have observed that a
variety of fetal mouse organs elaborate immunoreactive so-
matomedin C (Sm-C) into medium (3). Furthermore, it has
been shown that Sm-C/insulin-like growth factor I (IGF-I) is
synthesized by cultured human and rat fibroblasts (4-6).
These findings suggest that the somatomedins might act
through paracrine or autocrine mechanisms, having their
biologic actions at or near their sites of origin. If such mecha-
nisms are operative, alterations in somatomedin physiology
may be better reflected by estimation of tissue concentra-
tions than by measurement of concentrations in blood. Using
a newly devised method for extraction of Sm-C, we ad-
dressed these possibilities by comparing tissue concentra-
tions of immunoreactive Sm-C in normal rats and their hy-
pophysectomized littermates. In addition, we assessed the
tissue Sm-C response to the administration of growth hor-
mone in hypophysectomized rats.
MATERIALS AND METHODS
Animals. Hypophysectomized male Sprague-Dawley rats
and their normal littermates were purchased from Zivic-
Miller Labs (Allison Park, PA). Hypophysectomy was car-
ried out when the animals weighed =100 g. Animals were fed
standard laboratory chow ad lib, and provided water, each
liter of which contained 2.03 g of NaCl, 83.3 mg of KCl, 2.1
mg of CaCl, 16.7 mg of MgCl, and 50 g of sucrose. Two sets
of rats were used for the experiments. At the time of sacri-
fice, 48-50 days of age and 20 days after operation, the hy-
pophysectomized groups weighed 100.4 ± 9.8 g (mean ±
SD; n = 68) and 107.2 ± 8.2 g (n = 25). The mean weights for
the two groups of normal rats were 251.6 ± 17.7 g (n = 7) and
263.8 ± 18.6 g (n = 6). Completeness of hypophysectomy
was verified by direct examination of the sella turcica and by
RIA of serum Sm-C. The mean serum Sm-C concentrations
in the two groups of hypophysectomized rats were 2.26 ±
0.4% and 2.57 ± 0.44% of the values in the normal rats.
Experimental Design. Groups of six hypophysectomized
rats were injected intraperitoneally with ovine growth hor-
mone (oGH; S-11 provided by the Hormone Distribution
Program, National Institute of Arthritis, Diabetes, and Di-
gestive and Kidney Diseases) or vehicle (0.05 M NH4CO3,
pH 8.2). In the first experiment, 1 mg of oGH in 1 ml of
vehicle was administered, and rats were sacrificed by decap-
itation after 2, 4, 8, 12, 18, and 24 hr. As controls, one to
three rats that had been injected with vehicle were sacrificed
after each time interval. The injections were timed so that all
animals were sacrificed between 0900 and 1200 hr. Six addi-
tional hypophysectomized rats that were not injected were
sacrificed at the same time of day. In the second experiment,
groups of four to six hypophysectomized rats were adminis-
tered 10, 50, 100, or 250 ,ug of oGH, or were injected with
vehicle, and were sacrificed after 12 hr.
Blood was collected from all rats at the time of decapita-
tion, and immediately chilled in ice; sera were obtained by
centrifugation and stored at -200C until time of assay (within
1 wk). In the first experiment, brains, hearts, lungs, livers,
and kidneys were dissected and immediately frozen in liquid
nitrogen. The time from sacrifice to completion of dissection
was =90 sec. In the second experiment, lung, liver, and tes-
tes were removed from the hypophysectomized oGH-treated
rats. In the normal rats and hypophysectomized rats injected
with vehicle, perirenal fat pad, cervical lymph node, ilio-
psoas muscle, prostate, sternum, submaxillary gland, and
thymus were also removed. From sacrifice until collection of
all tissues, no more than 4 min elapsed. All tissues were fro-
zen, weighed, and stored at -20°C until extraction (within 4
wk).
Method of Tissue Extraction. Under liquid nitrogen, each
tissue was pulverized to a powder with a mortar and pestle,
and two aliquots of each tissue were weighed in tared poly-
styrene conical centrifuge tubes. One aliquot was saved for
determination of total protein by the method of Lowry (7)
and the other was extracted with acetic acid. Acetic acid was
used to extract Sm-C from tissue because plasma somatome-
Abbreviations: Sm-C, somatomedin C; oGH, ovine growth hor-
mone; IGF-I, insulin-like growth factor I.
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dins are liberated from their binding proteins by exposure to
acid (8-10) and bioassayable somatomedin has been extract-
ed from rat liver with acetic acid (11). Five milliliters of
chilled 1 M acetic acid was added for each gram of tissue,
yielding a final pH of 3.6-4.2. The mixture was shaken vigor-
ously, allowed to stand on ice for 2 hr, and, after centrifuga-
tion at 600 x g for 10 min, the supernate was removed by
pipette and saved. The precipitate was then subjected again
to extraction with fresh 1 M acetic acid. The two supernates
were combined, frozen at -700C, lyophilized to dryness, and
reconstituted with 0.05 M Tris-HCI buffer (pH 7.8) in a ratio
of 2 ml of buffer to 1 g of original tissue. Because variable
amounts of insoluble material (depending on the tissue) re-
main after reconstitution of the lyophilized material, the ex-
tract was clarified by centrifugation at 600 x g for 10 min.
Extracts were then frozen at -20'C and stored until RIA for
Sm-C (usually within 2 wk).
To determine whether additional Sm-C could be extracted
using a different procedure, the residues of liver, kidney, and
lung that had been subjected to extraction were sonicated
(Branson 185 Cell Disrupter for 45 sec at a setting of 3) in
assay buffer, and the supernatant was assayed. In these
three organs, the Sm-C measured in the original extract was
80.4-92.2% of that measured from the original extract plus
the reextracted precipitate. In an additional experiment, par-
tially purified Sm-C was added to aliquots of the liquid nitro-
gen frozen powder from liver and heart, and after extraction
>80% of the added Sm-C was quantified in the assay. When
Sm-C in the form of rat plasma was added to powdered
heart, liver, lung, and brain frozen in liquid nitrogen, recov-
eries of 91-128% were observed.
RIA for Sm-C. The RIA for Sm-C was carried out using a
nonequilibrium technique (12, 13). Sm-C used for iodination
and other studies had been purified to a specific activity of
27,000 units/mg and was judged by multiple criteria to be no
less than 90% pure (14). The standard is a lyophilized pool of
plasma from normal adult human blood donors (lot 1778-5;
Ortho Diagnostics). The activity in tissue extracts is ex-
pressed as units of immunoreactive Sm-C per g of tissue, in
which a unit is designated as the activity in 1 ml of the stan-
dard. Because normal adult rat serum has more Sm-C activi-
ty than human serum, the values reported for normal rat se-
rum are relatively high.
In rat serum our RIA reflects the growth-hormone depen-
dency of Sm-C (15). In the two groups of normal control rats,
Sm-C concentrations were 28.5 ± 5.4 units/ml (mean ± SD;
n = 7) and 28.7 ± 10 units/ml (n = 6); in hypophysectomized
littermates, they were 0.67 ± 0.12 units/ml (n = 16) and 0.74
± 0.12 units/ml (n = 6) (P < 0.0001). Binding proteins do not
appear to interfere with measurements in unextracted rat se-
rum because 97.5% of added Sm-C is measured when the
purified Sm-C is assayed in the presence of rat serum. In
addition, when subjected to acid chromatography (see be-
low), the immunoreactivity migrating in the region of free
Sm-C represented 99% and 106% of that measured in unex-
tracted serum from normal and hypophysectomized rats, re-
spectively. When rat serum was incubated with acetic acid in
a fashion identical to that used to extract tissues (4 hr at 4°C),
there was no change in the Sm-C concentration. On the basis
of these observations, we routinely assayed fresh unextract-
ed serum.
Hemoglobin Assay and Determination of Amount of Serum
in Each Tissue Extract. Hemoglobin concentrations of indi-
vidual tissues were determined on samples obtained from 14
rats that were age-matched to the rats used for Sm-C analy-
sis. These determinations were carried out on aliquots of
acetic acid extracts that had not been subjected to lyophiliza-
tion. As with Sm-C extraction, it was necessary to extract
hemoglobin on ice to prevent degradation. Hemoglobin con-
centration was determined using the modified benzidene as-
say method of Crosby and Furth (16). Rat hemoglobin (Sig-
ma) was used as the standard. The volume (in ml) of serum in
each ml of extract was calculated as follows:
[Hgk~ex 0.54,
0.1495
where [Hgkex is g of hemoglobin in 1 ml of extract, 0.1495 is
the average hemoglobin concentration (g/ml) of rat blood,
and 0.54 is the portion of rat blood that is serum (mean he-
matocrit = 46%).
To determine the efficiency of extraction of hemoglobin,
known amounts of hemoglobin in the form of blood frozen in
liquid nitrogen were added to powdered tissue from normal
animals before extraction with acetic acid. Recovery of add-
ed hemoglobin was 102% for heart and liver, 96% for lung,
and 61% for brain.
Column Chromatography. To separate immunoreactive
Sm-C from its binding proteins, representative tissue ex-
tracts and sera were chromatographed on a 1.6 x 40.5 cm
Sephadex G-50 (Pharmacia) column equilibrated in 1 M ace-
tic acid (8, 9). Two fractions were collected, lyophilized, and
reconstituted for assay. The first (Kd, 0-0.22) contains the
bulk of serum proteins and most of the Sm-C binding pro-
teins, while the second (Kd, 0.22-0.66) contains free Sm-C.
RESULTS
Observations on Extraction Methods. Maintaining pH be-
tween 3.6 and 4.2 appeared to be optimal for tissue Sm-C
extraction because at pH 2.6, only 65% and 62% as much
immunoreactivity was obtained from liver and kidney, re-
spectively, and 53% and 18% was obtained from each at pH
2.2. Pilot experiments also showed that substantially more
Sm-C was extracted from tissues frozen and pulverized in
liquid nitrogen than from iced and homogenized tissues
(about 3-fold for liver, 2-fold for kidney, and 5-fold for lung).
Likewise, there was evidence for loss of Sm-C when extrac-
tion was not carried out on ice.
To determine whether the immunoreactive Sm-C in tissue
extracts was being measured without interference by binding
proteins or other substances, experiments were done to
show that multiple concentrations of extracts from all tissue
studied produce serial dilution curves parallel to the human
plasma standard and to purified Sm-C. Also, when fixed vol-
umes of extracts from kidney, liver, heart, lung, and brain
were assayed in the presence of each of seven concentra-
tions of purified Sm-C, the mean recovery of the added Sm-
C ranged from 95.5% to 100.8%. In addition, the immunore-
active Sm-C recovered from acetic acid G-50 Sephadex col-
umns was equal to that measured in extracts, ranging from
90.5% to 97%.
Finally, to show that proteolytic enzymes in the extracts
were not capable of degrading 12 I-labeled Sm-C in the RIA,
and thereby causing a spurious increase in the apparent Sm-
C, 125I-labeled Sm-C was incubated with extracts under con-
ditions identical to the assay (72 hr at 4°C), and then precip-
itated with an excess of anti-Sm-C antibody. In each case,
125I-labeled Sm-C precipitates incubated with extracts
ranged from 96.5% to 100.2% of controls (125I-labeled Sm-C
incubated with buffer alone).
Based on the hemoglobin content in the extracts, the mean
volume of serum in each gram of tissue from normal animals
was 13.3 ± 1.3 ,ul (mean + SD; n = 13) for liver, 32.9 ± 4.4
,41 (n = 12) for lung, 6.9 ± 0.6 ,ul for kidney (n = 12), 33.3 ±
4.9 ,l (n = 12) for heart, and 2.33 ± 0.8 ,ul for brain (n = 6).
These are of the same magnitude as that observed using an-
other method for estimating contamination of tissue by blood
(17). For the other tissues, the serum concentration was 2.3
,ul per g of tissue or less. Using the Sm-C concentration in
serum, we calculated the percentage of extract Sm-C that
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could have been derived from serum Sm-C. On average, se-
-um Sm-C could have accounted for <0.2-47.8% (17 ± 2.4%
for liver, 35.4 ± 11.1% for lung, 7.4 ± 1.7% for kidney, 47.8
± 3.5% for heart, 24.4 ± 14% for brain, 16.3% for thymus,
12.3% for lymph nodes, 12.3% for muscle, and <3% for oth-
er tissue studied) of extractable Sm-C from normal tissue
and <0. 1-5.7% (3.96 ± 1.3% for liver, 4.4 ± 0.7 for lung, 0.7
± 0.4% for kidney, 5.7 ± 2.3% for heart, and <2.0 for all
other organs) from tissues from hypophysectomized ani-
mals. Because the Sm-C in serum from normal rats could
have made significant contributions to some tissues, the pos-
sible serum contribution was subtracted from the tissue con-
centration.
Tissue Sm-C Concentrations in Normal and Hypophysecto-
mized Rats. Sm-C concentration in hypophysectomized rats
were lower than those in normal rats in all tissues studied
except the brain (Table 1). These differences were highly sig-
nificant (P < 0.005) in all nonpooled organs in which statisti-
cal tests could be applied. Extracts from livers of hypophy-
sectomized rats had relatively less Sm-C (compared to nor-
mal) than any other organ. On the other hand, muscle,
thymus, and lymph nodes from hypophysectomized animals
exhibited the lowest absolute concentrations. There were no
significant differences between normal and hypophysecto-
mized rats in protein content per g of frozen tissue. The re-
sults of the study, therefore, are not changed when they are
expressed on the basis of tissue protein rather than weight.
Increase in Tissue Sm-C After Administration of oGH. In
four of the five solid tissues studied (kidney, liver, lung, and
heart), there was a significant increase in Sm-C in response
to the intraperitoneal administration of 1 mg ofoGH. In each
of ttoese tissues the peak response occurred after 12 hr (Fig.
1). In kidney, lung, and heart, a significant increment was
observed in animals sacrificed after 2 hr, while a sustained
increase began between 4 and 8 hr. The changes in tissue
Sm-C after administration of oGH consistently preceded
changes in serum Sm-C. In serum, the first significant in-
crease in Sm-C was observed at 4 hr; a sustained increase
began between 8 and 12 hr; and the maximal increment was
observed at 18 hr. Furthermore, tissue Sm-C concentrations
decreased long before serum concentrations.
The greatest Sm-C response to oGH occurred in kidney,
followed in descending order by liver, lung, and heart (Fig.
2). In a preliminary experiment directed at defining the dose
Table 1. Extractable tissue Sm-C concentrations in male rats
Sm-C, units/g*
Normal Hypophysectomized
Tissue Mean ± SD Mean ± SD % normal
Serumt 28.7 ± 0.98 0.74 ± 0.12f 2.6
Liver 1.91 ± 0.23 0.23 ± 0.08t 12.0
Lung 2.04 ± 0.86 0.57 ± 0.13t 27.9
Kidney 2.59 ± 0.80 0.77 ± 0.29* 29.7
Heart 0.92 ± 0.33 0.48 ± 0.14 52.2
Muscle (iliopsoas) 0.42 ± 0.05 <0.08 <19.1
Brain 0.26 ± 0.09 0.28 ± 0.04 107.7
Testes 1.88 ± 0.42 0.52 ± 0.32t 27.7
Prostate§ 1.06 0.40 37.7
Thymus§ 0.33 0.10 30.3
Lymph nodes§ 0.48 0.08 16.7
Cartilage (sternum)§ 0.67 0.53 79.1
Fat pad (perirenal) 0.67 ± 0.19 0.25 ± 0.10t 37.3
Submaxillary gland§ 1.73 0.78 45.1
*AIl values, except for pooled organs, represent six or seven organs.
tSerum values are expressed as units/ml.
tDifferences between Sm-C concentrations of normal and hypophy-
sectomized rats are significant (P < 0.005).
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FIG. 1. Tissue and serum Sm-C response to intraperitoneal ad-
ministration of oGH in hypophysectomized rats. Groups of six male
rats were injected intraperitoneally with 1 mg of oGH in 1 ml of
vehicle (0.05 M NH4CO3, pH 8.2) at time 0 and sacrificed at the
times indicated. The time 0 group is composed of rats that were not
injected. One to three animals injected with vehicle were sacrificed
at each time, and their Sm-C Values were, not different from the unin-
jected controls. Tissue Sm-C concentrations are in units/g (frozen
weight); serum concentrations are in units/ml. Significant differ-
ences between untreated and oGH-injected rats were as follows:
kidney, at 2.4, and 24 hr P < 0.01 and at 8, 12, and 18 hr P < 0.0005;
liver, at 8 hr P < 0.005, at 12 hr P < 0;0005, and at 18 hr P < 0.0125;
lung, at 2 hrP < 0.0025, at 8 hr P < 0.01, at 12 and 18 hr P < 0.0005,
and at 24 hrP < 0.025; heart, at 2 hrP < 0.05 and at 8, 12, and 18 hr
P < 0.025; brain, at 2, 4, 18, and 24 hrP < 0.01 (lower than control);
serum, at 4 hr P < 0.0125, at 12 and 24 hr P < 0.0005, and at 18 hr P
< 0.0025. Differences were determined by unpaired Student's t
tests.
response of tissue Sm-C, we injected hypophysectomized
rats with 0.1, 0.25, 0.5, or 1 mg of oGH. When the rats were
sacrificed at 8 hr, it appeared that a maximal or near-maxi-
mal response had occurred at all dosages above 0.1 mg (data
not shown). In a subsequent experiment (Fig. 3), we injected
groups of five rats with 10, 50, 100, or 250 ,ug of oGH and
assessed tissue Sm-C 12 hr later. In liver the mean Sm-C
concentrations fit a linear regression model (r = 0.95; P <
0.01), and in lung the mean values also fit a linear regression
model (r = 0.99; P < 0.01) if the 250-p.g oGH dose was ex-
cluded. In testes, which were collected as pools of five or-
gans, Sm-C concentrations were 1.13, 1.30, 2.18, and 2.13
units/g for the 10-, 50-, 100-, and 250-,ug oGH doses, respec-
tively. In the same group of animals, serum Sm-C concentra-
tions did not change compared to animals injected with vehi-
cle (0.74 ± 0.12 for vehicle controls; 0.74 + 0.31, 0.84 ±
0.29, 0.82 ± 1.8, and 0.74 + 0.03 units/ml for oGH doses of
10, 50, 100, and 250 ,ig, respectively; P value, not signifi-
cant.
DISCUSSION
Virtually all studies on the regulation of the somatomedins
have focused on their concentrations in serum. Although no
enriched tissue source has been found, these growth factors
have been considered to act by hormone-like endocrine
mechanisms, exerting their actions at locations distant to
their site(s) of origin. The observation that explants of multi-
ple fetal tissues and a variety of cultured cells produce im-
munoreactive somatomedins (4-6) led to the proposal that
Medical Sciences: D'Ercole et aL
Z)























a r n A el n In 11A0 2 4 8 12 18
HOURS AFTER oGH
FIG. 2. Magnitude of tissue and serum Sm-C response to intra-
peritoneal injection of 1 mg of oGH in hypophysectomized rats.
Data from the same animals shown in Fig. 1 are displayed as the
percent of control (time 0, noninjected animals). Note that the rise
and fall in the tissue concentrations of Sm-C precede similar fluctua-
tions in serum concentration.
these peptides exert their biological effects at or close to
their sites of origin (2), acting by paracrine or autocrine
mechanisms (18). The results reported in this study provide
further evidence that many tissues are capable of Sm-C syn-
thesis and by inference support the concept of a paracrine or
autocrine mechanism of action. The finding that concentra-
tions of Sm-C in tissues are growth-hormone dependent is
consistent with our understanding of somatomedin regula-
tion. Furthermore, because the time course of changes in
tissue Sm-C concentration in response to oGH administra-
tion precede those observed in serum, it appears that the
Sm-C derived from multiple tissues determines the serum
concentration. Although our data support the paracrine-au-
tocrine concept, they do not exclude an endocrine function
because somatomedin in the circulation could act on cells
distant from its site of origin.
Our ability to' detect differences between the Sm-C content
of tissue from normal and hypophysectomized rats, as well
as increments in Sm-C after administration of oGH, may be
due to the techniques used to preserve and extract this pep-
tide. Flash freezing in liquid nitrogen is likely to minimize in
vivo degradation, and it is possible that the Sm-C in pulver-
ized tissue is more accessible to acid extraction than it would
be in homogenates. We observed previously that liberation
of Sm-C from serum-binding proteins is optimal when the pH
is between 3.6 and 4.2 (10). The pH studies reported here
suggest that the same pH range is optimal for extraction of
somatomedin from tissue. Other evidence that these proce-
dures extract Sm-C from tissue and that the activity mea-
sured in the RIA is not artifactual includes, the observations
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FIG. 3. Tissue concentrations of Sm-C in liver and lung in re-
sponse to oGH.. Groups of hypophysectomized male rats (n = 5)
were injected intraperitoneally with 1 ml of vehicle or with 10, 50,
100, or 25Q ,ug of oGH (in 1 ml of vehicle) and sacrificed 12 hr later.
Results are expressed as units of Sm-C per g of frozen weight. In
liver, oGH increased Sm-C concentrations at all doses (P < 0.0005),
and the mean responses to each dose fit a linear regression model (r
= 0.95, P < 0.01; y = 0.59 + 0.0016x). In lung, the 50-, 100-, and
250-lig doses resulted in increased Sm-C concentrations (P < 0.005,
P < 0.005, and P < 0.05, respectively). The mean responses to the
10-, 50-, and 100-tig oGH doses also fit a linear regression model (r
= 0.99, P < 0.01; y = 0.72 + 0.0045x).
Sm-C, (ii) pure Sm-C and Sm-C from rat plasma are accura-
trely measured in the presence of extracts, and (iii) the
amount of extracted Sm-C measured in the RIA is equal to
that measured after extracted Sm-C has been separated from
binding proteins by gel chromatography in acid.
Perhaps the best evidence that the Sm-C measured in a
tissue extract actually originates in that tissue is the response
to oGH in hypophysectomized rats. Basal Sm-C concentra-
tions in kidney, lung, and heart of hypophysectomized rats
exceed those of whole blood, assuming that a gram of tissue
has a volume of 1 ml of blood and that serum occupies 54%
of the whole blood volume. At the time of the maximal re-
sponse to oGH (12 hr), the mean tissue levels in kidney,
lung, heart, and liver are, respectively, 6.1, 1.4, 1.5, and 1.3
times higher than whole blood.
In hypophysectomized rat tissue, maximal concentrations
of Sm-C were reached 12 hr after the administration of oGH.
This presumably is the result of local synthesis occurring 4-
12 hr after oGH administration. In heart, lung, and kidney,
significant increases in Sm-C also occurred after 2 hr and
conceivably caused the increase in serum concentrations ob-
served 2 hr later (at 4 hr). In light of the relatively long inter-
val between oGH injection and maximal increment in Sm-C,
we believe that the early increase of Sm-C does not repre-
sent de novo synthesis, especially since this response is not
sustained. It might be that the increment in Sm-C measured
after 2 hr represents peptide that has been released from a
precursor. Only in kidney was the early increase in Sm-C
sustained. Because kidney is probably the major site of Sm-
C degradation (19), this sustained increase as well as the
striking increment observed after 12 hr might represent in
part Sm-C filtered from serum for the purpose of degrada-
tion. In brain, the maximal Sm-C was not significantly differ-
ent from the basal concentration (at time 0). However, sig-
nificant fluctuations occurred because brain Sm-C concen-
trations fell below basal concentrations at 2 and 4 hr after
oGH administration. It is not clear how growth hormone
could directly effect these changes. In addition, they appear
not to result from serum-derived Sm-C because the two do
not coincide temporally.
To estimate the relative contribution of individual organs
to the serum Sm-C, we assumed that the plasma volume of a
100-g hypophysectomized rat was 3 ml. We calculated that
between 8 and 18 hr after the administration of oGH, the
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total Sm-C content of hyophysectomized rat serum in-
creased by 2 units. During this same interval, tissue concen-
trations peaked and declined. If one assumes that the decre-
ment in tissue Sm-C occurring between 12 and 18 hr results
from movement of Sm-C from tissue to blood, and calculates
the decrement in Sm-C per organ, the liver could then ac-
count for 55% of the peptide in the circulation, kidney for
6%, lung for 4%, and heart for 1%. Other tissues would have
to contribute the remaining 34%.
The observation that tissue Sm-C concentrations increase
in response to the administration ofoGH in dosages between
10 and 250 Aug is consistent with reports of the dose needed to
stimulate de novo protein synthesis (20). Specifically, rats
injected intraperitoneally with 200 ,Ag of bovine growth hor-
mone had an increase in protein synthesis in muscle and liver
beginning 30 min after hormone administration (21). Further-
more, bovine growth hormone in concentrations as low as
0.1 pug/ml stimulates the in vitro uptake of amino acids in rat
diaphragm (22).
The techniques we used to measure tissue concentrations
of Sm-C may be better for studying the regulation of this
peptide than measurement of levels in serum. Tissue Sm-C
concentrations appear to be quite dependent on growth hor-
mone status and, when growth hormone is administered, ex-
hibit changes greater than those that occur in serum. Studies
of changes in tissue concentration after alterations in nutri-
ent intake, administration of hormones or drugs, and other
manipulations of experimental animals may provide new in-
sights into the regulation of this growth factor and the con-
trol of growth.
We wish to thank Cary P. Cavender for technical assistance, Jud-
son J. Van Wyk and Marjorie E. Svoboda for providing purified Sm-
C, Stuart Handwerger for helpful discussions, and Dorothy Hill for
editorial assistance. This work was supported by Grant HD08299
from the National Institute of Child Health and Human Develop-
ment and Basic Research Grant 1-758 from the National Founda-
tion, March of Dimes. A.J.D. is a recipient of a Research Career
Development Award from the National Institute of Child Health and
Human Development (HD00435).
1. Clemmons, D. R. & Van Wyk, J. J. (1981) in Handbook ofEx-
perimental Pharmacology, ed. Baserga, R. (Springer, New
York), Vol. 57, pp. 161-208.
2. D'Ercole, A. J. & Underwood, L. E. (1981) in Fetal Endocri-
nology: ORPC Symposia on Reproductive Biology, eds. Novy,
M. J. & Resko, J. A. (Academic, New York), Vol. 1, pp. 155-
182.
3. D'Ercole, A. J., Applewhite, G. T. & Underwood, L. E.
(1980) Dev. Biol. 75, 315-328.
4. Atkison, P. R., Weidman, E. R., Bhaumick, B. & Bala, R. M.
(1980) Endocrinology 106, 2006-2012.
5. Clemmons, D. R., Underwood, L. E. & Van Wyk, J. J. (1981)
J. Clin. Invest. 67, 10-19.
6. Adams, S. O., Nissley, S. P., Handwerger, S. & Rechler,
M. M. (1983) Nature (London) 302, 150-153.
7. Lowry, 0. H., Rosebrough, N. J., Farr, A. L. & Randall,
R. J. (1951) J. Biol. Chem. 193, 265-275.
8. Hintz, R. L. & Liu, F. (1977) J. Clin. Endocrinol. Metab. 45,
988-995.
9. Zapf, J., Walter, H. & Froesch, E. R. (1981) J. Clin. Invest.
68, 1321-1330.
10. Chatelain, P. G., Van Wyk, J. J., Copeland, K. C., Blethen,
S. L. & Underwood, L. E. (1983) J. Clin. Endocrinol. Metab.
56, 376-383.
11. Vassilopolou-Sellin, R. & Phillips, L. S. (1982) Endocrinology
110, 582-589.
12. Furlanetto, R. W., Underwood, L. E., Van Wyk, J. J. &
D'Ercole, A. J. (1977) J. Clin. Invest. 60, 648-657.
13. Copeland, K. C., Underwood, L. E. & Van Wyk, J. J. (1980)
J. Clin. Endocrinol. Metab. 50, 690-697.
14. Svoboda, M. E., Van Wyk, J. J., Klapper, D. G., Fellows,
R. E., Grissom, F. E. & Schleuter, R. J. (1980) Biochemistry
19, 790-797.
15. Hurley, T. W., D'Ercole, A. J., Handwerger, S., Underwood,
L. E., Furlanetto, R. W. & Fellows, R. E. (1977) Endocrinol-
ogy 101, 1635-1638.
16. Crosby, W. H. & Furth, F. W. (1956) Blood 11, 380-383.
17. Sharpe, L. M., Culbreth, G. G. & Klein, J. R. (1950) Proc.
Soc. Exp. Biol. Med. 74, 681-685.
18. Sporn, M. B. & Todaro, G. J. (1980) N. Engl. J. Med. 303,
878.
19. D'Ercole, A. J., Decedue, C. J., Furlanetto, R. W., Under-
wood, L. E. & Van Wyk, J. J. (1977) Endocrinology 101, 247-
259.
20. Kostyo, J. L. & Nutting, D. F. (1974) in Handbook ofPhysiol-
ogy: Endocrinology, eds. Greep, R. 0. & Astwood, E. B.
(American Physiological Society, Washington, DC), Section 7,
Vol. 4, pp. 187-210.
21. Kostyo, J. L. & Nutting, D. F. (1973) Horm. Metab. Res. 5,
167-172.
22. Ahren, K., Albertsson-Wikland, K., Isaksson, 0. & Kostyo,
J. L. (1976) in Growth Hormone and Related Peptides, eds.
Pecile, A. & Muller, E. E. (Excerpta Medica, Amsterdam),
pp. 94-103.
Medical Sciences: D'Ercole et aL
